Novartis Q2 Sales +1% (cc); Reaffirms FY26 Guidance

Novartis reported solid second-quarter 2026 results, with net sales growing +1% in constant currencies to $14.4 billion, primarily driven by strong performance from key brands like Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio. Core operating income remained flat (cc) at $5.9 billion. However, net income declined -19% (cc) to $3.3 billion, and EPS fell -18% (cc) to $1.71, impacted by higher income taxes and interest expenses. The company reaffirmed its full-year 2026 guidance and highlighted significant pipeline advancements, including new approvals for Rhapsido and Itvisma, and strategic acquisitions.